DOI: 10.12890/2022_003216

Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature

Authors

  • Ali Al Sbihi DMC Sinai-Grace Hospital, Detroit, MI, USA
  • Nouraldeen Manasrah DMC Sinai-Grace Hospital, Detroit, MI, USA
  • Dahlia Sano Karmanos Cancer Centre/Wayne State University, Detroit, MI, USA

aalsbihi@dmc.org

Keywords

COVID-19, multiple myeloma, lenalidomide

Abstract

We present a case series of three multiple myeloma (MM) patients on lenalidomide for maintenance therapy who were at high risk of coronavirus disease 2019 (COVID-19) complications and mortality. However, our patients had minor symptoms after testing positive for COVID-19 although they were unvaccinated. We think that lenalidomide might have a protective effect against severe COVID-19 symptoms.

View the entire article

Downloads

Published

2022-03-09

How to Cite

1.
Al Sbihi A, Manasrah N, Sano D. Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature. EJCRIM [Internet]. 2022 Mar. 9 [cited 2026 Nov. 3];9(3). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3216

Most read articles by the same author(s)